 |
 |
【摘要】目的 探讨复方贞术调脂胶囊对大鼠非酒精性脂肪肝的影响,为其临床用药提供依据。方法 取SD大鼠60只,随机分成正常组、模型组、复方贞术调脂胶囊高、中、低组、非诺贝特组。除正常组外,其他组采用高脂乳剂灌胃复制大鼠非酒精性脂肪肝模型,造模同时复方贞术调脂胶囊高、中、低组、非诺贝特组连续给药8周后,测定肝脏胆固醇（TC)、三酰甘油（TG),并计算肝指数,光镜下观察肝脏病理学变化。结果 复方贞术调脂胶囊能降低肝脏TC和肝指数。肝脏病理切片结果显示复方贞术调脂胶囊组肝细胞脂肪变性、水样变性及坏死和炎症细胞浸润等病理表现均有所减轻,明显轻于模型组。结论 复方贞术调脂胶囊对非酒精性脂肪肝有较好的防治作用。
【关键词】 复方贞术调脂胶囊 非酒精性脂肪肝 病理 肝指数
The influence of compound Zhenzhu Tiaozhi capsules on nonalcoholic fatty liver disease (NAFLD) in rats
CHEN Fangchao,GUO Jiao,YANG Chaoyan, GONG Mengjuan,LU Xiaoping,TANG Chunping
(Section of Pharmacology of Chinese Medicine,Guangdong Pharmaceutical College, Guangzhou,Guangdong 510006,China)
Abstract:Objective To study the effects of compound Zhenzhu Tiaozhi capsules on nonalcoholic fatty liver disease (NAFLD) in rats. Methods 60 SD Rats were randomly divided into 6 groups: normal group, model group, compound Zhenzhu Tiaozhi capsules high dose group, moderate dose group, low dose group, and the fenofibrate group. Rats model with nonalcoholic fatty liver disease were established with administration of high fat emulsion by gavage. The rats in the treatment groups were administered with test drugs．After 8 weeks，liver cholesterol (TC), triglyeride (TG) were determined and liver index was calculated. Pathological changes in liver were observed by light microscopy. Results The liver TC and liver index of the rats administered with compound Zhenzhu Tiaozhi capsules were significantly reduced, and pathological changes were significantly ameliorated in the rats administered wit compound Zhenzhu Tiaozhi capsules. Conclusions Compound Zhenzhu Tiaozhi capsules has better therapeutic effects on nonalcoholic fatty liver disease in rats医.学全.在.线网站www.lindalemus.com．
Key words:compound Zhenzhu Tiaozhi capsule; nonalcoholic fatty liver; pathology; liver index
近年来,随着人们饮食结构、生活方式的改变,肥胖症、糖尿病、高脂血症患者日益增多,导致非酒精性脂肪肝（nonalcoholic fatty liver，NAFL)的发病率也逐年增加,已成为现今社会的多发病、常见病［1］。研究表明：NAFL在较短期内可发展为不可逆的肝损害,其肝纤维化的发生率高达25％［2］。因此积极发现和防治脂肪肝对阻止慢性肝病进展有着十分重要的意义。
脂肪肝多伴有高脂血症,大部分需要降血脂治疗［3］。复方贞术调脂胶囊为我院郭姣教授经验方, 临床具有较好的降血脂疗效。该组方已获得国家发明专利授权(ZL2004100512504),前期实验中已证实复方贞术调脂胶囊具有调节血脂代谢异常作用,对高脂血症有防治作用［4］。在此基础上，本实验旨在进一步探讨复方贞术调脂胶囊对高脂饮食诱导的NAFL大鼠肝脏脂质和肝脏病理学形态变化的影响,为临床治疗非酒精性脂肪肝提供科学依据。
